COMP <GO>
AMLX vs IRON // RSI-14 & 200D SMA MOMENTUM
Amylyx Pharmaceuticals Inc. (NASDAQ) VS. Disc Medicine Inc. (NASDAQ) • 15-METRIC TALLY: AMLX 2
— IRON 3
▲ RSI-14 & 200D SMA MOMENTUM LEADER: IRON
LAST: $28.04 (-2.84%) • MKT CAP: $3.62B
rsi-technicals
51.9
LAST: $78.62 (-2.75%) • MKT CAP: $3.59B
rsi-technicals
62.4
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AMLX VS. IRON)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | AMLX | IRON | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -27.50% | -7.50 | IRON | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -3.43% | -4.93% | +1.50 | AMLX | /fcf-yield <GO> |
| Operating Margin | — | -22.90% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -20.60% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | — | 16.50% | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 26.00 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 5/9 | -2.00 | IRON | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum ACTIVE | 51.9 | 62.4 | -10.50 | IRON | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.90 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 20.0x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $3.62B | $3.59B | $32.0M | AMLX | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | AMLX REV | IRON REV | AMLX GROSS % | IRON GROSS % | AMLX FCF | IRON FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $429.2M | $660.9M | — | — | -$123.5M | -$181.3M |
| FY 2024 | $87.4M | $363.2M | 93.2% | — | -$167.8M | -$94.4M |
| FY 2023 | $380.8M | $255.2M | — | — | $11.9M | -$73.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AMLX // BETA —
IRON // BETA 0.90